Vendor Intelligence Report: Atomik Labz

Executive summary

Atomik Labz is not a brand-wide yes or no; it is a product-specific vendor with a messy counterparty trail. Across 42 Finnrick lab tests, Atomik Labz shows a 79% pass rate (33 pass / 9 fail). The cleanest support sits in Retatrutide and GHK-Cu, while BPC-157 and CJC-1295 are the weak reads; ratings also lose ground under stricter purity and fill thresholds, so the exact peptide and batch matter.

The non-lab record is the sharper hook. Archived site captures show Atomik Labz moving through two JE Production names before the live footer, Terms, and Privacy Policy dropped the entity name entirely. Florida exact-name searches did not find either recovered name, and the wider registry trail did not identify a public operating company behind Atomik.

The report also maps the wider cluster. The Atomik-to-Solution Peptides link rests on shared address, policy text, infrastructure, and discount-code signals; Warrior Peptides adds address and policy cross-references but weaker common-governance evidence. A buyer switching brands may not diversify operator risk as much as the labels imply, even though no direct FDA warning letter or federal court action was found in the searched record.

Retatrutide illustrates the split. Finnrick's history is strong, yet the public complaint trail repeats a 24mg batch identifier with zero-effect allegations and account-blocking claims. The practical read is batch verification plus recourse planning, especially because Atomik's stack includes high-risk payment processing, cryptocurrency, a login-gated storefront, and a wide affiliate-code network with uneven disclosure.

Inside the full report:

• Appendix A per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 9 products
• Wayback capture analysis tracing JE Production Ventures, JE Production Enterprises, and current entity-name removal
• Registry and negative-search trail across Sunbiz, OpenCorporates, CourtListener, FDA, ImportYeti, and RDAP
• Solution Peptides and Warrior Peptides network analysis covering address, policy-text, infrastructure, and code signals
• Complaint, affiliate, and payment-rail review covering account terminations, Retatrutide batch claims, Bankful, crypto, and disclosure gaps

Risk assessment

• Customer-recourse risk — high: Multiple review/forum reports describe account termination after quality complaints, with TOS human-use language used to deny refunds or replacements.
• Legal-counterparty opacity — high: Live site does not disclose a verifiable legal counterparty; archived footers name JE Production Ventures/Enterprises, but registry searches found no matching entity.
• Affiliate-promotion risk — high: Recurring Atomik Labz referral links/codes show limited or no disclosure, including /aff/167, /aff/65, /aff/79 and ZOE25/PEPSFIRE codes.
• Product-quality risk — BPC-157 and CJC-1295 — high: Finnrick records BPC-157 at 1 pass / 3 fail and CJC-1295 at 3 pass / 2 fail with a 37.14% rating.
• Product-quality risk — Ipamorelin and PT-141 — medium: Finnrick records Ipamorelin at 3 pass / 2 fail and PT-141 at 2 pass / 2 fail, materially weaker than Atomik's stronger GLP-1/GHK-Cu results.
• Unresolved batch-complaint risk — Retatrutide n1024n — medium: June 2026 Trustpilot complaint echoes March Reddit allegations of zero-effect 24mg Retatrutide from batch n1024n, despite Atomik's otherwise 8 pass / 0 fail Retatrutide record.
• Network-disclosure risk — medium: Evidence of coordinated anonymization across Atomik Labz, Solution Peptides, and Warrior Peptides, with shared address and boilerplate signals.